Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th Business Wire BETHESDA, Md. -- May 13, 2013 Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP), a global pharmaceutical company, today announced that it will host a meeting to discuss the recent opioid-induced constipation (OIC) indication approval for its flagship product, AMITIZA, on May 20, 2013, from 9:00 to 10:30AM ET in Orlando, FL. Members of Sucampo’s management team and two key outside experts will provide a market update, overview of the scientific data, and clinical perspectives relevant to OIC. If you would like to attend the event in Orlando, please RSVP to email@example.com as space is limited. Those interested in accessing the live audio webcast of the teleconference may do so at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar and should log on 10 to 15 minutes before the meeting begins in order to download any software required. Presentation slides will be available via the webcast links. A replay of the webcast will also be available on the Company’s website for several days after the live event. Alternatively, participants may dial 866-515-2907 (domestic) or 617-399-5121 (international) and use passcode 24996242. A replay of the teleconference will be available by dialing 888-286-8010 (domestic) or 617-801-6888, passcode 41707791, approximately two hours after the teleconference concludes. The archive of the teleconference will remain available for 30 days. About Opioid Induced Constipation (OIC) OIC is a common adverse effect of chronic opioid use. Binding of opioids to peripheral opioid receptors in the gastrointestinal tract results in absorption of electrolytes, such as chloride, and subsequent reduction in small intestinal fluid. In addition, activation of enteric opioid receptors results in abnormal GI motility. Together, these processes result in OIC, which is characterized by infrequent and incomplete evacuation of stool, hard stool consistency, and straining associated with bowel movements. About lubiprostone (AMITIZA^®) AMITIZA (lubiprostone) is a prostone, a locally acting chloride channel activator, indicated for the treatment of chronic idiopathic constipation (CIC) in adults and OIC in adults with chronic, non-cancer pain (24 mcg twice daily) and for irritable bowel syndrome with constipation (8 mcg twice daily) in women 18 years of age and older in the United States. In Japan, lubiprostone (24 mcg twice daily) is indicated for the treatment of chronic constipation (excluding constipation caused by organic diseases). In Switzerland, lubiprostone (24 mcg twice daily) is indicated for the treatment of CIC. In the U.K., lubiprostone (24 mcg twice daily) is indicated for the treatment of CIC and associated symptoms in adults. About Sucampo Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com. AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. Sucampo Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by reference. Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor, 1-240-223-3718 firstname.lastname@example.org
Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th
Press spacebar to pause and continue. Press esc to stop.